References
- Adamo V, Scimone A, Maisano R, et al. Etoposide, 1-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother 1999; 11: 74–77.
- Planting AS, van der Burg ME, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. Br J Cancer 1996; 73: 1265–1267.
- Passalacqua R, Bisagni G, Cocconi G, Boni C, Di Blasio B, Ceci G. Cisplatin and etoposide in advanced colorectal car-cinoma. Ann Oncol 1991; 2: 687–688.
- Posner M, Slapak CA, Browne MJ, et al. A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-flu-orouracil, and VP-16 in colorectal cancer. Am J Clin Oncol 1990; 13: 455–458.
- Colucci G, Maiello E, Giuliani F, Cifarelli RA, Giotta F. Carboplatin and etoposide in previously treated colorectal can-cer patients. Tumori 1995; 81: 36–38.
- Zelkowitz RS, Posner MR, Cummings F, Seitz J, Weitberg AB. A Phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma. Am J Clin Oncol 1989; 12: 492–493.
- Stuart K, Posner M, Campbell K, Huberman M. Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol 1995; 18: 300–302.
- Inaba M, Mitsuhashi J, Kawada S, Nakano H. Different modes of cell killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 1994; 85: 187–193.
- Sinkule JA. Etoposide: a semi-synthetic epipodophyllo-toxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 1984; 4: 61–73.
- Jeremic B, Acimovic L, Mijatovic L. Carboplatin and etoposide in advanced colorectal carcinoma. A phase II study. Cancer 1993; 71: 2706–2708.
- Zaniboni A, Labianca R, Pancera G, et al. Oral etopo-side as second-line chemotherapy for colorectal cancer: a GIS-CAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente. J Chemother 1995; 7: 246–248.
- Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–217.
- Kaplan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966; 50: 163–170.
- Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418.
- Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continu-ous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–1412.
- Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ. Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-3-is(2-chlorethyl)-1-nitrosourea and vin-cristine. J Natl Cancer Inst 1975; 54: 69–74.
- Macdonald JS, Kisner DF, Smythe T, Woolley PV, Smith L Jr, Schein PS. 5-Fluorouracil (5-FU), methyl-CCNU and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU. Cancer Treat Rep 1976; 60: 1597-1602.
- Baker LH, Talley RW, Matter R, et al. Phase III com-parison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU versus methyl-CCNU plus bolus week-ly 5-FU: a Southwest Oncology Group study. Cancer 1976; 38: 1–7.
- Kemeny N, Yagoda A, Braun J. Metastatic colorectal carcinoma: A prospective trial of methyl CCNU, 5-fluorouracil (5FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep). Cancer 1983; 51: 20–25.